Clinical trial
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic…
NCT00003670 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00003670 |
|---|---|
| Title | Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer |
| Official title | Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Primary Peritoneal Cavity Cancer |
| Intervention type | Drug |
| Interventions | arzoxifene hydrochloride |
| Start date | Oct 1, 1998 |
| Completion | Jan 1, 2001 |
| First posted | May 21, 2004 |
| Last update posted | Jun 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: